Research Topics
| M H WeismanSummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Newly diagnosed rheumatoid arthritisM H Weisman
Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Ann Rheum Dis 61:287-9. 2002
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritisMichael H Weisman
Cedars Sinai Medical Center, Los Angeles, California, USA
Arthritis Rheum 54:607-12. 2006..This study investigated whether risk genotypes for folate-dependent enzymes are associated with the toxicity of MTX in patients with rheumatoid arthritis (RA)...- Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohortWonuk Lee
Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Ann Rheum Dis 66:633-8. 2007.... - Heritability patterns in hand osteoarthritis: the role of osteophytesMariko L Ishimori
Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
Arthritis Res Ther 12:R180. 2010..The objective of the present study was to assess heritability of clinical and radiographic features of hand osteoarthritis (OA) in affected patients and their siblings... - The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort studyMatthew L Mundwiler
North Suburban Rheumatologists, Des Plaines, IL 60016, USA
Arthritis Res Ther 11:R94. 2009..Similar analyses were performed for bone marrow edema, predicting a subsequent MRI erosion. Descriptive results of other lesions are reported... - Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot studyMatthew L Mundwiler
Rockford Orthopedic Associates, 324 Roxbury Rd, Rockford, IL 61107, USA
Arthritis Res Ther 11:R177. 2009..Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls... - Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyMichael H Weisman
Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Clin Ther 25:1700-21. 2003.... 
Development and validation of a case ascertainment tool for ankylosing spondylitisMichael H Weisman
Cedars Sinai Medical Center, Los Angeles, California, USA
Arthritis Care Res (Hoboken) 62:19-27. 2010..We tested questions derived from a comprehensive literature review and an advisory board in a case-control study designed to identify patients with AS from among patients with chronic back pain (CBP)...- What are the risks of biologic therapy in rheumatoid arthritis? An update on safetyMichael H Weisman
Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Rheumatol Suppl 65:33-8. 2002..At this time, treating physicians must carefully weigh the benefits of these new biologics against their risks, particularly in patients at risk of infection... - Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritisMichael H Weisman
Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
J Rheumatol 33:2162-6. 2006..To determine the mechanism of action of abatacept, we analyzed changes in the serum levels of inflammatory biomarkers in the patients enrolled in this trial... - Development of a new instrument for rheumatoid arthritis: the Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA)Michael H Weisman
Cedars Sinai Health System, Los Angeles, California 90048, USA
Arthritis Rheum 49:78-84. 2003.... - Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007D E Furst
David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA
Ann Rheum Dis 66:iii2-22. 2007 - The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohortI Moldovan
Loma Linda University, California, USA
Lupus 20:1285-92. 2011..0001). Conclusion: Depression, and not disease activity, appears to have a major influence on quality of life in both Hispanic and Caucasian patients in this lupus cohort... - Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrumentC F Chiou
Cerner LifeSciences, Beverly Hills, California, USA
Arthritis Rheum 55:856-63. 2006..It captures 3 additional domains (social well-being, pain/discomfort, and fatigue), which allow for measuring all important aspects of health-related quality of life... - Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006D E Furst
David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA
Ann Rheum Dis 65:iii2-15. 2006 - Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 yearsJ D Posalski
Cedars Sinai Medical Center, Los Angeles, CA, USA
Lupus 18:516-21. 2009..When evaluating organ system subsets separately, MMF improved disease activity in the first year, but had little effect in preventing new organ-specific flares, with most flares taking place in second and third year of treatment... - Benefits of leflunomide in systemic lupus erythematosus: a pilot observational studyC F Remer
Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Lupus 10:480-3. 2001..Blood pressure was unchanged. Leflunomide was efficacious and safe in this cohort of SLE patients after 2-3 months of therapy. Placebo-controlled trials of longer duration are indicated... - Review: Male systemic lupus erythematosus: a review of sex disparities in this diseaseL J Lu
Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Lupus 19:119-29. 2010..This review discusses these findings and sex disparities in SLE that appear to be especially noteworthy and pertinent to our understanding of male SLE... - The B cell in systemic lupus erythaematosus: a rational target for more effective therapyC B Driver
Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Ann Rheum Dis 67:1374-81. 2008..Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile... - High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosusN Firooz
Cedars Sinai Medical Center, Los Angeles, California, USA
Lupus 20:588-97. 2011..Elevated hsCRP levels can be used as a predictor of active infection in SLE patients with a high specificity. We review the relationship between IL-6 and hsCRP production in lupus patients... - Validation of a rheumatoid arthritis health-related quality of life instrument, the CSHQ-RAS M Russak
Division of Rheumatology, Cedars-Sinai Health System, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Arthritis Rheum 49:798-803. 2003..70-0.90). CONCLUSION: These results support the construct validity, discriminant validity, and reliability of the CSHQ-RA as a measure that captures the impact of RA on patients' health-related quality of life... - Depression predicts self-reported disease activity in systemic lupus erythematosusF N Carr
California School of Professional Psychology, Alliant International University, Los Angeles, California, USA
Lupus 20:80-4. 2011..Longitudinally, depression alone predicted self-reported disease activity. These data suggest that depression may play a significant role in the health status of SLE patients and serve as an important target for clinical intervention... - Potential therapeutic uses of interleukin 1 receptor antagonists in human diseasesD S Hallegua
Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA 90048, USA
Ann Rheum Dis 61:960-7. 2002.... - Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot studyD J Wallace
Department of Medicine/Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA
Rheumatology (Oxford) 40:743-9. 2001..Because IL-8 promotes sympathetic pain and IL-6 induces hyperalgesia, fatigue and depression, it is hypothesized that they may play a role in modulating FM symptoms... - Cigarette smoking and rheumatoid arthritisS A Albano
Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Semin Arthritis Rheum 31:146-59. 2001..The example of p53 may be a first step in the discovery of additional links between environmental triggers and phenotypic expression of chronic illness... - Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?M L Ishimori
Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Lupus 16:436-43. 2007..The therapeutic implications for separating PRES from stroke or cerebritis are important. We propose that PRES should be considered in the differential diagnosis in SLE patients with new-onset neurologic signs and symptoms... - The lowest surviving birth weight reported in a systemic lupus erythematosus patient: a review of the literatureJ Spiegel
Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Lupus 16:52-5. 2007..This report represents the lowest birth weight pregnancy survival in a lupus patient and the first case of a survival in the second trimester with preeclampsia and HELLP syndrome... - Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLES A Lander
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Lupus 11:340-7. 2002..These results suggest that patients with SLE can be safely and effectively treated with celecoxib; however, further studies are needed to assess the effectiveness and safety of all NSAIDs in SLE... - Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialMichael E Weinblatt
Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Arthritis Rheum 48:35-45. 2003..To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor alpha antibody, in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite treatment with MTX... - Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trialJeffrey P Harris
Division of Otolaryngology Head and Neck Surgery, University of California, San Diego, CA 92103 8895, USA
JAMA 290:1875-83. 2003..Methotrexate has emerged as the benchmark agent but has not been rigorously evaluated for hearing improvement in patients with AIED... - Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trialJoel M Kremer
The Center for Rheumatology, LLP, 1367 Washington Avenue, Suite 101, Albany, NY 12206, USA
Ann Intern Med 137:726-33. 2002..Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate... - Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugsHarold E Paulus
Division of Rheumatology, UCLA Medical Center, Los Angeles, California 90095, USA
J Rheumatol 31:470-81. 2004..To quantitate patient retention and radiographic progression rates in serial hand/wrist radiographs of patients with rheumatoid arthritis (RA) who were not being treated with disease modifying antirheumatic drugs (DMARD)... - New therapies for treatment of rheumatoid arthritisJosef S Smolen
Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Lancet 370:1861-74. 2007..Novel therapeutic strategies in conjunction with optimised disease assessment for better treatment of rheumatoid arthritis and an outlook into potential future targets are also presented... - A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseasesMichael H Weisman
Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Rheumatology (Oxford) 46:1122-5. 2007..To evaluate the safety of etanercept in patients with rheumatoid arthritis (RA) and concomitant comorbidities... - Do all drugs and treatments for rheumatoid arthritis have the same efficacy?Michael H Weisman
Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Nat Clin Pract Rheumatol 4:298-9. 2008 - Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled studyStanley Cohen
Division of Rheumatology, St Paul University Medical Center, Dallas, Texas 75235, USA
Otol Neurotol 26:903-7. 2005..Data from a guinea pig model of AIED and a recent open label trial of etanercept suggested potential treatment benefit. Based on these preliminary results, we conducted a pilot placebo controlled trial of etanercept in AIED patients... - Progress toward the cure of rheumatoid arthritis? The BeSt studyMichael H Weisman
Arthritis Rheum 52:3326-32. 2005 - Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni
Friedrich Alexander University, Erlangen Nuremberg, Germany
Arthritis Rheum 52:1227-36. 2005..To investigate the efficacy and tolerability of infliximab therapy for the articular and dermatologic manifestations of active psoriatic arthritis (PsA)... - The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previoFerdinand C Breedveld
Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
Arthritis Rheum 54:26-37. 2006..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment... - Validity of self-administered quality of well-being scale in musculoskeletal diseaseDominick L Frosch
University of California, San Diego, CA, USA
Arthritis Rheum 51:28-33. 2004..QWB-SA items can be used to calculate an arthritis-specific score. The QWB-SA can be used to gain generic information for cost-utility analysis and disease-specific outcomes information for patients with arthritis... - Ruminating on rheumatoid arthritis and transplantationRichard K Burt
Northwestern University, Feinberg School of Medicine, Chicago, IL 60208, USA
Clin Immunol 115:129-30. 2005 - Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisalMichael H Weisman
Evidence-Based Medicine Working Groups in Rheumatology, Beverly Hills, CA, USA
J Rheumatol 30:1739-47. 2003..Although consistency between reviewers was good on both guidelines, inter-guideline discrepancies were noted and reviewers reported some difficulty in using the operationalized format... - Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndromeCai Sheng Lu
University of California, Los Angeles, CA 90095, USA
Arthritis Rheum 52:4018-27. 2005..To test the hypotheses that some plasmin-reactive anticardiolipin antibodies (aCL) may bind to tissue plasminogen activator (tPA) and that some of the tPA-reactive aCL may inhibit tPA activity... - Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler
Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
N Engl J Med 353:2219-28. 2005..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable... - Impact of ankylosing spondylitis on work and family life: comparisons with the US populationMichael M Ward
National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
Arthritis Rheum 59:497-503. 2008..To examine the impact of ankylosing spondylitis (AS) on work disability, nonparticipation in the labor force, marriage, divorce, and childbearing... - Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni
Clinical Immunology, Schering Plough Corporation, Kenilworth, New Jersey 07033 0530, USA
J Rheumatol 35:869-76. 2008..To investigate longterm efficacy/safety of infliximab over 2 years in patients with active psoriatic arthritis (PsA)... - Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosusJoel Schiffenbauer
Center for Drug Evaluation and Research, FDA, Rockville, Maryland 20850, USA
Arthritis Rheum 50:2415-22. 2004 - Lack of linkage of IL1RN genotypes with ankylosing spondylitis susceptibilityLi Jin
University of Cincinnati Cincinnati, OH, USA
Arthritis Rheum 50:3047-8. 2004 - Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosisVanessa L Malcarne
Department of Psychology, San Diego State University, CA 92120 4913, USA
J Rheumatol 34:359-67. 2007..To examine physician-assessed medical signs and patient-reported medical symptoms as correlates of 3 quality of life (QOL) outcomes in patients with systemic sclerosis (SSc): disability, pain, and psychosocial adjustment... - ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitisDesiree van der Heijde
University Hospital Maastricht, and the Care and Public Health Research Institute of the University Maastricht, Maastricht, The Netherlands
Arthritis Rheum 52:386-94. 2005 - Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritisWonuk Lee
Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Nat Clin Pract Rheumatol 2:298-9. 2006 - The predictive power of anti-cyclic citrullinated peptide antibodies: window into understanding gene/ environment/immunity interactionsWonuk Lee
J Rheumatol 33:1216-8. 2006 - Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literatureJessica E Nord
Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, Los Angeles, California, USA
Semin Arthritis Rheum 33:336-51. 2004..The cases presented here, one with biopsy and one without, illustrate the utility of endomyocardial biopsy in HCQ-treated SLE patients with cardiac complaints to ensure accurate diagnosis and appropriate management... - Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritisDaniel O Clegg
Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
N Engl J Med 354:795-808. 2006..The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis... - Geode of the femur: an uncommon manifestation potentially reflecting the pathogenesis of rheumatoid arthritisWonuk Lee
Division of Rheumatology, Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
J Rheumatol 33:2541-4. 2006..We review the literature of large femoral geodes and what this particular manifestation may reflect about the pathogenesis of RA...